+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Chronic Kidney Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Kidney Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Acute Pyelonephritis - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Pyelonephritis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Hepatitis B Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatitis B Virus Infection - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Alport Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Alport Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Acute Kidney Injury (AKI) - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Kidney Injury (AKI) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Alcoholic Hepatitis - Pipeline Insight, 2024 - Product Thumbnail Image

Alcoholic Hepatitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Anemia in Chronic Kidney - Pipeline Insight, 2024 - Product Thumbnail Image

Anemia in Chronic Kidney - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2024 - Product Thumbnail Image

Acute On Chronic Liver Failure (ACLF) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Kidney Transplant Rejection - Pipeline Insight, 2024 - Product Thumbnail Image

Kidney Transplant Rejection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Acute Liver Failure - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Liver Failure - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Hepatorenal syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatorenal syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
End-Stage Kidney Disease - Pipeline Insight, 2024 - Product Thumbnail Image

End-Stage Kidney Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Homocystinuria - Pipeline Insight, 2024 - Product Thumbnail Image

Homocystinuria - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
Anemia Associated with Chronic Kidney - Pipeline Insight, 2024 - Product Thumbnail Image

Anemia Associated with Chronic Kidney - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Hepatitis B - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatitis B - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Alcoholic steatohepatitis - Pipeline Insight, 2024 - Product Thumbnail Image

Alcoholic steatohepatitis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Chronic Hepatitis C Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Hepatitis C Virus Infection - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 75 Pages
  • Global
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more